Wells Fargo & Company Bio Atla, Inc. Transaction History

Wells Fargo & Company

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.88 - $3.46 $3,769 - $6,937	2,005 Added 14.75%	15,595 $53,000
Q4 2023 Feb 09, 2024	BUY	$1.27 - $3.18 $3,415 - $8,551	2,689 Added 24.67%	13,590 $33,000
Q3 2023 Nov 13, 2023	SELL	$1.7 - $3.07 $10,142 - $18,315	-5,966 Reduced 35.37%	10,901 $18,000
Q2 2023 Aug 15, 2023	BUY	$2.83 - $3.87 $46,842 - $64,056	16,552 Added 5254.6%	16,867 $50,000
Q1 2023 May 12, 2023	BUY	$2.3 - $8.25 $9 - $33	4 Added 1.29%	315 $0
Q4 2022 Feb 13, 2023	BUY	$6.29 - $11.01 $459 - $803	73 Added 30.67%	311 $2,000
Q3 2022 Nov 14, 2022	BUY	$2.94 - $11.87 $73 - $296	25 Added 11.74%	238 $1,000
Q2 2022 Aug 12, 2022	SELL	$2.13 - $5.38 $200 - $505	-94 Reduced 30.62%	213 $0
Q1 2022 May 16, 2022	SELL	$4.38 - $18.78 $24,050 - $103,120	-5,491 Reduced 94.71%	307 $1,000
Q4 2021 Feb 14, 2022	BUY	$19.0 - $30.95 $109,079 - $177,683	5,741 Added 10071.93%	5,798 $114,000
Q3 2021 Nov 15, 2021	SELL	$29.44 - $43.74 $29 - $43	-1 Reduced 1.72%	57 $1,000
Q2 2021 Aug 16, 2021	SELL	$38.07 - $56.17 $135,453 - $199,852	-3,558 Reduced 98.4%	58 $2,000
Q1 2021 May 13, 2021	BUY	$32.41 - $70.91 $117,194 - $256,410	3,616 New	3,616 $184,000

17.3M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $62.4M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.